Raymond L. Comenzo, MD
Dr. Raymond Comenzo received his medical degree from Boston University School of Medicine. He completed his internship and residency in medicine at Boston City Hospital, followed by his fellowship in hematology/oncology at New England Medical Center. Dr. Comenzo is professor of medicine and pathology at Tufts University School of Medicine and director of the Blood Bank and Stem Cell Processing Laboratory.
Dr. Comenzo is board certified in internal medicine, medical oncology, and hematology. He is on the Scientific Advisory Board, International Myeloma Foundation; Board of Directors, Amyloidosis Foundation, and the Eastern Clinical Oncology Group (ECOG), Myeloma Committee. In addition he holds memberships in the Massachusetts Medical Society, American Society of Hematology (ASH), and the American Association of Blood Banks.
Dr. Comenzo’s research mainly focuses on autologous stem cell transplantation for systemic AL-amyloidosis, association of immunoglobulin light chain variable region germline gene use and organ tropism in AL-amyloidosis, defining the “fitness costs” to clonal plasma cells exacted by producing AL light chains and on the impact of proteasome inhibitors on such cells, novel model of plasma cell apoptosis triggered by knockdown of Ig light chain expression, pre-clinical evaluations of monoclonal antibodies elotuzumab (Bristol) and daratumumab (Janssen) with NK cells from SCT patients as effectors and lipidoid nanoparticle delivery systems targeting human plasma cells.
Representative Publications:
A Novel Xenograft Mouse Model for Testing Approaches Targeting Human Kappa Light-Chain Diseases
Stigmata of Amyloidosis; External Manifestations of Internal Disease
A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain Amyloidosis
Daratumumab Binds to Mobilized Cd34+ Cells of Myeloma Patients in Vitro Without Cytotoxicity or Impaired Progenitor Cell Growth
Beyond Neod001 for Systemic Light-Chain Amyloidosis
